# Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma

> **NCT05123131** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Cancer Trials Ireland** · enrollment: 54 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Isatuximab
- **DRUG:** Bortezomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone (IV)

## Key facts

- **NCT ID:** NCT05123131
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-01
- **Primary completion:** 2025-06-24
- **Final completion:** 2027-12-15
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-07-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05123131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05123131, "Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05123131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*